Programmatic offers digital health companies reach and efficiency that manual buying cannot equal – real-time bidding across display, video, audio, and native inventory at a scale no direct-buy team can reproduce. Yet the open supply chain that keeps programmatic inexpensive is also where health-data exposure, ad fraud, and poor-quality inventory exist. We build and manage the programmatic stack to buy efficiently, keep sensitive health signals out of the bidstream, and connect spend to activated patients rather than impressions.
Real-time bidding may expose condition and treatment signals through the open exchange before anyone detects it
Every programmatic bid request can carry contextual and behavioral signals to hundreds of exchange partners and data brokers, and a health-adjacent site visit, a symptom search retargeting pixel, or a condition-based segment can turn into a de-facto health data leak with no single team member responsible for catching it. Consumer health privacy laws now treat inferred condition data as regulated, not just diagnosis codes in a medical record. Most digital health marketing teams built their programmatic stack around performance goals and never audited what the bidstream itself reveals. The fix has to be in the media plan and the pixel setup, not a policy document nobody follows during trafficking.
A significant portion of programmatic spend goes to made-for-advertising sites and bot traffic that never reaches an actual patient
The programmatic supply chain runs through exchanges, resellers, and ad tech intermediaries that take a cut before your ad ever loads, and a large share of that inventory is low-quality arbitrage sites or invalid traffic built to harvest impressions rather than deliver them to real people. Teams that buy programmatic through open auction with no supply-path controls routinely lose a third or more of budget to inventory that could never have produced a patient. In digital health, where CAC targets are already tight, that waste is not a rounding error – it is the difference between a channel that works and one that gets cut.
Health-claim requirements cover every programmatic format, while most creative pipelines were not designed to review them at scale
A programmatic buy typically runs dozens of creative sizes and formats across display, video, and audio simultaneously, and health-category claim restrictions on conditions, outcomes, and treatments apply to every one of them. A claim that clears review on a landing page can still get an ad rejected or flagged across exchanges when it ships as a 300×250 banner or a 15-second video cut. Teams that treat programmatic creative like performance-marketing creative – fast iteration, minimal review – end up with disapprovals, wasted trafficking time, and inconsistent messaging across formats. The review process has to scale with the format count, not lag behind it.
Programmatic reports track impressions and clicks, but seldom reveal which supply paths and segments actually generated a patient
Standard DSP dashboards report delivery and click-through rate by default, which tells you the campaign ran but not which exchanges, publishers, or audience segments actually converted into activated patients. Digital health funnels already have long consideration windows, and layering opaque programmatic reporting on top makes it nearly impossible to know which part of the buy to cut and which to scale. Teams either keep spending on the whole stack because they cannot isolate what works, or cut programmatic entirely because the reporting never proved it did. Neither decision is based on real signal.
We begin by auditing the current programmatic stack – DSP setup, pixel and segment configurations, and the supply paths now in use – to identify where health-adjacent data is being shared and where spend is leaking into low-quality inventory.
Then, we rebuild the data governance layer. We configure pixels, audience segments, and bid requests so condition, treatment, and symptom-level signals do not pass to exchanges or data brokers without appropriate consent handling, and we document the data flow so it withstands a privacy review, not merely a launch review.
Next, we curate the supply path. Rather than buying through the open auction on every exchange connected to a DSP, we create private marketplace deals and supply-path controls around publishers offering verified, brand-safe, health-appropriate inventory. We also remove resellers and made-for-advertising sites built solely to consume budget.
For creative, we establish a review pipeline that evaluates every format – display, video, audio, native – against health-claim rules before trafficking instead of after an exchange flags it. Creative is built once around defined claim boundaries, then adapted across formats and sizes without reopening the compliance debate for each variant.
For measurement, we link DSP-level delivery data with your real funnel and activation data, allowing reports to show which supply paths, segments, and creative actually generated a patient – rather than only an impression or click. This makes it possible to narrow the stack to what performs instead of operating the entire buy on faith.
Unlike a standard programmatic trading desk, we manage the complete stack – data governance, supply curation, creative compliance, and measurement – as a unified system designed for a regulated category, rather than applying a generic media-buying service to health without modification.
Programmatic waste and compliance risk share the same underlying cause: an open supply chain that no one curated. Address supply paths and data governance together, and both issues decline at the same time.
We manage programmatic advertising through a 90-day sprint designed to establish an ongoing, curated buy. The initial 30 days cover audit and governance: we map existing data flows and supply paths, rebuild pixel and segment configurations to stop sensitive signals from leaking, and identify made-for-advertising inventory that is currently consuming budget. Days 30 to 60 concentrate on reconstructing the buy: we launch private marketplace deals with vetted publishers, create a health-claim creative review pipeline across formats, and eliminate open-auction spend directed toward unverified supply. From days 60 to 90, the focus moves to measurement and optimization: we connect DSP delivery data with funnel and activation data, then shift budget toward the supply paths and segments that genuinely produce patients.
Rather than operating like a generic trading desk focused on delivery and click-through rate, we prioritize the supply chain and data governance because, in digital health, they determine whether a buy is both defensible and efficient. We design the creative compliance process to grow with the number of formats instead of falling behind, and our reporting connects activated patients to specific supply paths rather than aggregated impressions.
The opening 30 days focus on auditing. We map your existing DSP setup, pixel and segment configurations, and supply paths, then provide a candid assessment of where health-adjacent data is exposed and where spend is reaching low-quality inventory. You receive a clear picture of the starting point, not an unclear pledge to improve.
Days 30 to 60 are dedicated to rebuilding. We reconfigure data governance, establish curated private marketplace deals, and create the cross-format creative review pipeline. We need your team to provide access to the current DSP account, existing creative assets or production support, and legal or compliance approval of the health-claim boundaries guiding our work.
During days 60 to 90, the emphasis moves to measurement and optimization. We link delivery data with your funnel and activation data, then begin redirecting spend from underperforming supply paths to those that are actually converting. Most engagements extend beyond the initial sprint because programmatic optimization compounds – supply paths become more efficient as data grows – and a typical first build lasts three to six months.
Our cadence features a weekly working session with your growth and compliance leads, plus regular reports covering supply-path performance, creative disapprovals, and activated-patient results. We work within your current media rhythm so programmatic supports the broader paid mix rather than functioning as an isolated buy.
If your digital health company needs programmatic advertising leadership, we should talk.
Let us take a custom approach to your growth goals by assembling and leading the best-in-class marketing team to support your next stage.
We bill a fixed monthly management fee based on the audit, supply-path curation, and continued optimization, while media spend is managed separately through your DSP. The fee scales according to the complexity of the supply-path rebuild and the number of creative formats being rotated.
The audit and governance rebuild are completed within the first 30 days, with the curated buy launching during the 90-day sprint. Savings from eliminating made-for-advertising inventory generally appear quickly because they directly reduce wasted spend, while activated-patient volume follows the usual consideration window of your funnel.
We operate directly within your current DSP account instead of creating a parallel account, preserving your team's control and visibility. We require access to existing pixel and segment configurations, legal or compliance approval of claim boundaries, and either creative assets or production support.
A conventional trading desk focuses on delivery and click-through rate within the DSP's default open auction. We prioritize data governance and supply-path curation because, in a regulated category, those factors determine whether the buy can be efficient and defensible simultaneously.
We link DSP delivery data with your funnel and activation data, enabling reports to identify which supply paths, segments, and creative variants actually generated a patient rather than merely an impression or click. Made-for-advertising and invalid-traffic inventory is found and eliminated instead of being reported as delivered reach.
This service is suited to digital health companies in roughly the 5M to 100M ARR range that are already using programmatic or considering it and need their buy to remain efficient and defensible under current health-data rules. It performs best when sufficient budget exists for a curated private marketplace buy rather than only a small open-auction test.
Tuesday, September 29, 2026
Frank Growth – Episode 239 – Your Back Office Is Obsolete with Adam Spector
Tuesday, September 22, 2026
Frank Growth – Episode 238 – The Best Kept Secret Sport with Ozge Erturk
Tuesday, September 15, 2026
Frank Growth – Episode 237 – Stop Buying Users Who Leave with Michelle Matthews
Tuesday, July 21, 2026
Frank Growth – Episode 229 – Longevity Medicine’s Dirty Secret with Jim Donnelly
Ready to unlock your growth?
Book Free Call